corp_html/multi/Profile-antiinfectives2.htm

<p>PLIVA's research into anti-inflammatory agents is divided into four programs. 
  In three of the programs, Locally-acting steroids, Anti-inflammatory agents
  and Inhibitors of TNF-alpha secretion, compounds with excellent therapeutic 
  activity in relevant disease models of asthma and rheumatoid arthritis have 
  been identified.</p>
<p>In the <b>Locally-acting steroids program</b>, molecules have been discovered 
  that demonstrate efficacy similar or superior to currently marketed
locally-acting steroids when applied 
  locally.</p>
<p>In the <b>Anti-inflammatory program</b>, compounds with excellent 
  anti-inflammatory activity were discovered throughout the testing when applied 
  orally. A new synthetic pathway, enabling the synthesis of a chemically pure 
  compound and the initiation of a derivatization strategy, has been found and 
  is being extensively utilized.</p>
<p>In the <b>Inhibitors of TNF-alpha secretion program</b>, several classes of 
  compounds have been discovered that inhibit the secretion of TNF-alpha <i>in 
  vivo</i> and have demonstrated good activity in the animal model of rheumatoid 
  arthritis. Additional derivatization may provide a development candidate with 
  higher safety and no adverse events.</p>
<p>Finally, in the <b>Tyrosine phosphorylation program</b>, a collaboration with 
  <a href="http://www.signalpharm.com">Signal Pharmaceuticals</a> has been
initiated.</p>
1	<p>PLIVA's research into anti-inflammatory agents is divided into four programs.
2	In three of the programs, Locally-acting steroids, Anti-inflammatory agents
3	and Inhibitors of TNF-alpha secretion, compounds with excellent therapeutic
4	activity in relevant disease models of asthma and rheumatoid arthritis have
5	been identified.</p>
6	<p>In the <b>Locally-acting steroids program</b>, molecules have been discovered
7	that demonstrate efficacy similar or superior to currently marketed
8	locally-acting steroids when applied
9	locally.</p>
10	<p>In the <b>Anti-inflammatory program</b>, compounds with excellent
11	anti-inflammatory activity were discovered throughout the testing when applied
12	orally. A new synthetic pathway, enabling the synthesis of a chemically pure
13	compound and the initiation of a derivatization strategy, has been found and
14	is being extensively utilized.</p>
15	<p>In the <b>Inhibitors of TNF-alpha secretion program</b>, several classes of
16	compounds have been discovered that inhibit the secretion of TNF-alpha <i>in
17	vivo</i> and have demonstrated good activity in the animal model of rheumatoid
18	arthritis. Additional derivatization may provide a development candidate with
19	higher safety and no adverse events.</p>
20	<p>Finally, in the <b>Tyrosine phosphorylation program</b>, a collaboration with
21	<a href="http://www.signalpharm.com">Signal Pharmaceuticals</a> has been
22	initiated.</p>